Navigation Links
Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
Date:9/12/2011

ass="discStyle" type="disc">
  • Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)       
    • Abstract # 7141, Poster Session: Genitourinary Malignancies - Other
    • Sunday, September 25, 2011, 2:00-4:30pm CEST, Poster Area  

    • Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma
      • Abstract # 6576, Poster Session: Gastrointestinal Malignancies - Non-colorectal Cancer
      • Monday, September 26, 2011, 9:30am-12:00pm CEST, Poster Area

    About Radium-223 Chloride

    Radium-223 chloride is an investigational pharmaceutical containing an alpha-particle emitting nuclide in development for cancer patients with bone metastases. In September 2009, Bayer signed an agreement with Algeta ASA (Oslo, Norway) for the development and commercialization of radium-223 chloride. Under the terms of the agreement, Bayer will develop, apply for global health authority approvals, and commercialize radium-223 chloride globally, while Algeta retains an option for up to 50/50 co-promotion and profit-sharing in the United States.

    Radium-223 chloride is an investigational agent and is not approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or other Health Authorities.  It was granted fast track designation by the FDA in August 2011.

    About Regorafenib

    Regorafenib is an investigational oral multi-kinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases (TK)(i) currently being investigated in clinical trials for its potential to treat patients with various tumor typ
    '/>"/>

    SOURCE Bayer HealthCare
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Nick Jonas and Bayer HealthCare Announce "Simple Inspirations" Contest to Motivate and Support Those Newly Diagnosed with Diabetes
    2. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
    3. Bayer HealthCare Provides Nearly $2.5 Million to Advance Hemophilia Research and Patient Care
    4. Bayer Study Reveals Gaps in Perception of Veterinary Care Between Vets and Pet Owners
    5. Bayer Announces Farnam Companies Agreement to Halt Disputed Bio Spot® Ads
    6. Bayers Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
    7. Bayers Discrimination Lawsuit Now Requires Extra-Strength Cure
    8. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
    9. Bayer HealthCare to Sponsor World Federation of Hemophilia Global Training Program and Donate Kogenate® FS, Antihemophilic Factor (Recombinant), Commercially Valued At More Than $7 Million
    10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
    11. Two New Studies in the British Medical Journal Find That Bayers Yaz and Yasmin Birth Control Pills Have an Increased Risk of Blood Clot
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
    (Date:10/22/2014)... JERUSALEM , October 22, 2014 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused ... today reported positive top-line clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... United States under a U.S. Food ...
    (Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
    Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
    ... Cytogen,Corporation (NASDAQ: CYTO) today announced that five ... major medical meetings. The,data will include various ... lexidronam injection) in combination settings for,the treatment ... and multiple myeloma, as well as data ...
    ... from Serial Outpatient Infusion Study in Patients with,Chronic ... Cardiology 56th Annual Scientific Session --, MOUNTAIN VIEW, ... Scios Inc. announced today that an exploratory,920-patient, Phase ... on the primary endpoint, a composite of death ...
    Cached Medicine Technology:New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 2New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 3New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 4New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7
    (Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
    (Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
    (Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Not getting the ... ulcerative colitis, a new study suggests. Those who ... eight hours per night may be more prone to ... intestines, researchers report. The study authors concluded that duration ... considered among patients with inflammatory bowel diseases. "Both ...
    (Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
    (Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
    Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
    ... Nursing Productivity in the Treatment of Renal Disease , ... ... 2009 -- iSirona®, an innovative provider of data automation solutions ... agreement with NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer ...
    ... provide services to all segments of the population , ... ST. Louis, ... its Dental Hygiene Education program in March. Accredited by the American Dental ... College. This program launch comes on the heels of Missouri College,s move ...
    ... year,s annual programme sees bigger than ever commitment to marketing spend Hallmark ... marketing drive in support of its annual ,Cards For A Cure™, campaign. ... which will have donated 3/4 million pounds to two breast cancer charities ... cards ) , ...
    ... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced ... from Friday, February 27, 2009 to Tuesday, March 24, 2009, ... first mailed to shareholders by CTI on or about February ... shareholders and so that all shareholders receive at least 20 ...
    ... 26 Old Republic International Corporation (NYSE: ... Directors approved the payment of the regular quarterly cash dividend ... payable on March 13, 2009 to shareholders of record on ... the higher rate initially approved for the second quarter of ...
    ... TechnologyWASHINGTON, Feb. 26 President Obama,s first proposed ... expands eligibility for health care to an additional ... meets the need for continued growth in programs ... and provides the resources to deliver quality health ...
    Cached Medicine News:Health News:iSirona Signs Reference Selling Agreement with NxStage 2Health News:Missouri College Brings new Dental Hygiene Program to Saint Louis 2Health News:Hallmark Cards Increases Investment In Cards For a Cure™ with Major Advertising and PR Campaign for Mother's Day 2009 2Health News:Hallmark Cards Increases Investment In Cards For a Cure™ with Major Advertising and PR Campaign for Mother's Day 2009 3Health News:Cell Therapeutics Reschedules Special Meeting 2Health News:Cell Therapeutics Reschedules Special Meeting 3Health News:President's 2010 Budget Request Strongly Supports VA Programs 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: